Dan Grander

Stockholm, AB, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib.

Silencing of CEBPB-AS1 modulates CEBPB expression and resensitizes BRAF-inhibitor resistant melanoma cells to vemurafenib.

Journal: Melanoma research

Published: May 30, 2020

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma.

PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma.

Journal: Scientific reports

Published: May 07, 2020

Irreversible TrxR1 inhibitors block STAT3 activity and induce cancer cell death.

Irreversible TrxR1 inhibitors block STAT3 activity and induce cancer cell death.

Journal: Science advances

Published: April 23, 2019

Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.

Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing cytarabine efficacy.

Journal: EMBO molecular medicine

Published: February 01, 2019

Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib.

Targeting autophagy by small molecule inhibitors of vacuolar protein sorting 34 (Vps34) improves the sensitivity of breast cancer cells to Sunitinib.

Journal: Cancer letters

Published: May 04, 2018

An antisense RNA capable of modulating the expression of the tumor suppressor microRNA-34a.

An antisense RNA capable of modulating the expression of the tumor suppressor microRNA-34a.

Journal: Cell death & disease

Published: February 27, 2018

STAT3 differential scanning fluorimetry and differential scanning light scattering assays: Addressing a missing link in the characterization of STAT3 inhibitor interactions.

STAT3 differential scanning fluorimetry and differential scanning light scattering assays: Addressing a missing link in the characterization of STAT3 inhibitor interactions.

Journal: Journal of pharmaceutical and biomedical analysis

Published: January 24, 2018

Metabolic reprogramming of acute lymphoblastic leukemia cells in response to glucocorticoid treatment.

Metabolic reprogramming of acute lymphoblastic leukemia cells in response to glucocorticoid treatment.

Journal: Cell death & disease

Published: January 19, 2018

The molecular dynamics of long noncoding RNA control of transcription in PTEN and its pseudogene.

The molecular dynamics of long noncoding RNA control of transcription in PTEN and its pseudogene.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: August 30, 2017

RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients.

RNAi prodrugs targeting Plk1 induce specific gene silencing in primary cells from pediatric T-acute lymphoblastic leukemia patients.

Journal: Journal of controlled release : official journal of the Controlled Release Society

Published: April 17, 2017

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.

PD-L1 is commonly expressed and transcriptionally regulated by STAT3 and MYC in ALK-negative anaplastic large-cell lymphoma.

Journal: Leukemia

Published: March 28, 2017

Identification of novel small molecules that inhibit STAT3-dependent transcription and function.

Identification of novel small molecules that inhibit STAT3-dependent transcription and function.

Journal: PloS one

Published: March 13, 2017

Showing 1-12 of 43

Last Updated: 09/26/2026